Galux was established in 2020 with the incorporation of molecular design technology that has been honed over a period of 15 years at Seoul National University. This technology leverages the integration of AI, physics, and chemistry to produce exceptional results, as evidenced by its performance in the CASP and CAPRI competitions.
Built on a foundation of advanced research and development capabilities, Galux is currently developing a drug design platform that incorporates protein structure prediction, protein-protein interaction prediction, and protein-ligand interaction prediction technologies. The company is also focused on identifying and developing novel therapeutics for incurable and rare diseases through its AI-based drug design platform.
If you are interested in reaching out to Galux, please do not hesitate to contact us via email at contact@galux.co.kr.
Company Details
- Employees
- 30
- Founded
- -
- Address
- 1837, Nambusunhwan-Ro, F3,korea, Republic Of
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.galux.co.kr/
- Keywords
- Artificial Intelligence, Neural Network, Machine Learning, Drug Discovery, Drug Design, Drug Development, Biological Drug, Protein Drug, Antibody Drug, Enzyme Drug, Chemical Drug, Small Molecule Drug, Large Molecule Drug, protein design, antibody design, de novo design.
- HQ
- Gwanak-gu, Seoul
Galux Questions
Galux's website is https://www.galux.co.kr/
Galux's LinkedIn profile is https://kr.linkedin.com/company/galuxdesign
Galux has
30 employees.
View email and phone details for 30
employees at Galux.
Galux's industry is
Biotechnology Research
Galux's top competitors are
Xaira Therapeutics,
Standigm,
Lunit Cancer Screening,
Floatic,
Attentionx,
Aivis,
Zefit Inc.,
Biomatz,
Palleos,
Cureverse Inc..
Galux's categories are Biotechnology Research
Galux's founding year is 2020
